All In Biotech

NDA 203491 · Harrow Eye

Ilevro

Nepafenac · Ophthalmic · Nonsteroidal Anti-inflammatory Drug

Last checked: Nov 20, 2026Latest source record: Nov 10, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Oct 16, 2012

Approved uses

1

Original approval plus efficacy supplements

Registered trials

57

12 Phase 3, 1 recruiting

FAERS reports

1,718

588 serious, 39 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 1, 2026.

ILEVRO ® 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery. ILEVRO ® 0.3% is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery ( 1 ).

Mechanism: After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, a NSAID. Nepafenac and amfenac are thought to inhibit the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production.

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 16, 2012 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLetterLabel
1 products under this application
  • ILEVRO · NEPAFENAC 0.3% · SUSPENSION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nepafenac" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye pain376
  • drug ineffective119
  • vision blurred110
  • off label use65
  • eye irritation64
  • product quality issue58
  • visual impairment55
  • liquid product physical issue53
  • cataract52
  • fatigue48
  • chronic kidney disease41
  • incorrect dose administered41

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200817
20102
20124
201311
201424
201570
2016232
2017577
2018158
2019188
2020143
202180
202243
202354
202456
202539
202620

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ilevro (Nepafenac)

2024 spending

$14.9M

Beneficiaries

21,018

37,389 claims

Per beneficiary

$707

$122.67 per unit

View as table
YearSpending
2020$0
2021$16,323,977
2022$20,025,719
2023$20,449,838
2024$14,850,188

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 83 on PubMed

Sponsor: Harrow Eye

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.